$31.0M
$2.6M
4.4x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
Community pharmacy located in the Boroughs. This pharmacy is located on a street with heavy foot traffic...
Why we like it
- Earnings quality is strong on paper, with $2.6M EBITDA on $31M revenue producing an 8.4% margin that beats typical retail pharmacy economics where PBM clawbacks crush margins. Prescription revenue is recurring and tied to chronic-condition refills, which produces a predictable cash flow base rather than one-off transactions.
- The moat here is the prescription file and the location. A high-foot-traffic borough street with an established Rx book and embedded prescriber and patient relationships is hard to replicate, and patients rarely switch pharmacies once their refills and insurance are dialed in.
- Pharmacies are about as recession-resistant as retail gets. People do not stop taking blood pressure, diabetes, or cholesterol medication in a downturn, and most scripts are insurance-covered, which insulates revenue from consumer discretionary swings.
- There is real operator upside for a buyer who knows reimbursement. Independent pharmacies are routinely under-optimized on payor contracts, generic purchasing, and front-end retail merchandising, meaning an active owner can expand margin without chasing new revenue.
How to improve it
- Audit and renegotiate PBM and payor reimbursement contracts immediately, since this is where independent pharmacies bleed the most margin. Joining or upgrading a buying group or PSAO can improve generic acquisition cost and reimbursement terms within the first quarter.
- Build or expand high-margin specialty and clinical services such as compounding, immunizations, medication therapy management, and adherence packaging. These services carry far better margins than commodity dispensing and increase patient stickiness in a dense urban market.
- Launch a medication synchronization and auto-refill program to lock in chronic-care patients and smooth refill volume. Sync programs measurably increase adherence, reduce abandoned scripts, and lift refills per patient, which directly grows the recurring Rx base.
- Optimize the front-end retail mix on a heavy-foot-traffic street by curating higher-margin OTC, durable medical equipment, and convenience SKUs. The location is already driving walk-ins, so the question is dollars-per-visit, not bodies through the door.
- Pursue 340B eligibility or contract pharmacy arrangements if the patient population qualifies, as this can materially improve margins on a subset of scripts. In borough neighborhoods with safety-net providers nearby, this is often an overlooked lever.
- Implement workflow automation and central-fill or robotic dispensing to reduce labor cost per script. Pharmacist and tech labor is the largest controllable expense, and automation lets the team handle more volume without proportional headcount growth.
- Capture more of the local payor and prescriber network through targeted outreach to nearby clinics, specialists, and long-term care facilities. Adding even one assisted-living or clinic referral relationship can add a meaningful, sticky script volume.
Diligence notes
- Scrutinize payor mix and reimbursement concentration line by line, including Medicaid, Medicare Part D, and commercial split. A heavy Medicaid skew in a borough pharmacy creates reimbursement and rate-change risk, and any single-payor concentration is a material vulnerability to model.
- Verify the EBITDA is clean of DIR fee timing, PBM clawbacks, and add-backs that overstate normalized cash flow. Pharmacy EBITDA frequently looks better than reality once retroactive DIR fees and reconciliation adjustments are properly accrued, so demand reconciled payor statements.
- Confirm lease terms, remaining length, and renewal options for the high-foot-traffic location, since the entire value thesis rests on this address. A short or expiring lease, or a landlord with renewal leverage, could gut the goodwill you are paying for.
- Examine prescription file portability and customer concentration, including whether any single prescriber or facility drives an outsized share of script volume. Loss of a key prescriber relationship at transition is the fastest way to impair an independent pharmacy.
- Assess pharmacist and key staff retention, licensing, and DEA/state board compliance history. Independent pharmacy operations depend on a small licensed team, and any open compliance issues, audit findings, or controlled-substance flags must be fully cleared before close.
- Pressure-test the 4.41x multiple against generic deflation trends and ongoing PBM reimbursement pressure that have squeezed independents nationally. Confirm revenue and margin are stable or growing rather than benefiting from a one-time tailwind that may not persist post-close.